Get started
DIVI S LABORATORIES LTDDIVI S LABORATORIES LTDDIVI S LABORATORIES LTD

DIVI S LABORATORIES LTD

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

DIVISLAB chart


Full chart

DIVISLAB upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.72 T‬ INR
Dividend yield (indicated)
0.46%
Price to earnings Ratio (TTM)
78.70
Basic EPS (TTM)
82.55 INR
Net income (FY)
‪21.91 B‬ INR
Revenue (FY)
‪93.60 B‬ INR
Shares float
‪126.65 M‬
Beta (1Y)
0.75

About DIVI S LABORATORIES LTD


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Satchandra Kiran Divi
Website
divislabs.com
Headquarters
Hyderabad
Founded
1990
ISIN
INE361B01024
FIGI
BBG000DJVYM0
Divi's Laboratories Ltd. is a holding company, which engages in the manufacture of active pharmaceutical ingredients, intermediates, and nutraceutical. It also provides manufacturing of generic APIs, nutraceutical ingredients, and custom synthesis for big pharma. The company was founded by Murali Krishna Prasad Divi on October 12, 1990 and is headquartered in Hyderabad, India.

Check out other big names from the same industry as DIVISLAB.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

DIVISLAB news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of DIVISLAB is 6,592.00 INR — it has increased by 1.52% in the past 24 hours. Watch DIVI S LABORATORIES LTD stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NSE exchange DIVI S LABORATORIES LTD stocks are traded under the ticker DIVISLAB.
DIVISLAB stock has fallen by −1.61% compared to the previous week, the month change is a 2.14% rise, over the last year DIVI S LABORATORIES LTD has showed a 46.95% increase.
We've gathered analysts' opinions on DIVI S LABORATORIES LTD future price: according to them, DIVISLAB price has a max estimate of 7,750.00 INR and a min estimate of 4,098.00 INR. Watch DIVISLAB chart and read a more detailed DIVI S LABORATORIES LTD stock forecast: see what analysts think of DIVI S LABORATORIES LTD and suggest that you do with its stocks.
DIVISLAB reached its all-time high on Jun 12, 2025 with the price of 6,862.50 INR, and its all-time low was 7.75 INR and was reached on Mar 12, 2003. View more price dynamics on DIVISLAB chart.
See other stocks reaching their highest and lowest prices.
DIVISLAB stock is 2.28% volatile and has beta coefficient of 0.75. Track DIVI S LABORATORIES LTD stock price on the chart and check out the list of the most volatile stocks — is DIVI S LABORATORIES LTD there?
Today DIVI S LABORATORIES LTD has the market capitalization of ‪1.72 T‬, it has decreased by −2.66% over the last week.
Yes, you can track DIVI S LABORATORIES LTD financials in yearly and quarterly reports right on TradingView.
DIVI S LABORATORIES LTD is going to release the next earnings report on Aug 11, 2025. Keep track of upcoming events with our Earnings Calendar.
DIVISLAB earnings for the last quarter are 24.90 INR per share, whereas the estimation was 22.63 INR resulting in a 10.01% surprise. The estimated earnings for the next quarter are 21.26 INR per share. See more details about DIVI S LABORATORIES LTD earnings.
DIVI S LABORATORIES LTD revenue for the last quarter amounts to ‪25.85 B‬ INR, despite the estimated figure of ‪25.62 B‬ INR. In the next quarter, revenue is expected to reach ‪24.99 B‬ INR.
DIVISLAB net income for the last quarter is ‪6.62 B‬ INR, while the quarter before that showed ‪5.89 B‬ INR of net income which accounts for 12.39% change. Track more DIVI S LABORATORIES LTD financial stats to get the full picture.
Yes, DIVISLAB dividends are paid annually. The last dividend per share was 30.00 INR. As of today, Dividend Yield (TTM)% is 0.46%. Tracking DIVI S LABORATORIES LTD dividends might help you take more informed decisions.
DIVI S LABORATORIES LTD dividend yield was 0.52% in 2024, and payout ratio reached 36.35%. The year before the numbers were 0.87% and 49.78% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. DIVI S LABORATORIES LTD EBITDA is ‪29.68 B‬ INR, and current EBITDA margin is 31.71%. See more stats in DIVI S LABORATORIES LTD financial statements.
Like other stocks, DIVISLAB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade DIVI S LABORATORIES LTD stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So DIVI S LABORATORIES LTD technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating DIVI S LABORATORIES LTD stock shows the buy signal. See more of DIVI S LABORATORIES LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.